Skip to content

Database release

Updated current and draft version of the database with FDA oncology approvals from May and June, thus far, 2025.

View on GitHub

Database content updates

Added entries:

  • (FDA) Taletrectinib for the treatment of patients with ROS1-positive non-small cell lung cancer.
  • (FDA) Telisotuzumab vedotin for the treatment of patients with high c-Met protein overexpression non-squamous non-small cell lung cancer.
  • (FDA) Avutometinib in combination with defactinib for the treatment of patients with KRAS-mutant low-grade serous ovarian cancer (G12C, G12V).